PDUFA dates February 2024: FDA calendar and catalysts.
2 PDUFA dates fell in February 2024: Amtagvi® (February 24), roluperidone (February 26). The FDA calendar also recorded 38 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in February 2024
| PDUFA date | Company | Ticker | Drug | Indication | Source |
|---|---|---|---|---|---|
| February 24, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | IOVA | Amtagvi® (lifileucel) | SEC 8-K Exhibit 99.1, filed 2025-08-07 | |
| February 26, 2024 | Minerva Neurosciences, Inc. | NERV | roluperidone (MIN-101) | SEC Form 10-Q, filed 2025-08-14 |
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
February 2024: other FDA decisions and filings
February 2024: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Feb 2024Month disclosed | apraglutide | IRWD | Topline readout | — | Positive | SEC Form 10-Q |
| Feb 2024Month disclosed | nomlabofusp (CTI-1601) | LRMR | Topline readout | — | Positive | SEC Form 10-Q |
| Feb 2024Month disclosed | RT-111 | RANI | Topline readout | inflammatory conditions | Positive | SEC Form 10-K |
| Feb 2024Month disclosed | allergies (EPI-17) | SPRY | Topline readout | — | Met primary endpoint | SEC Form 10-Q |
| Feb 2024Month disclosed | — | TARS | Topline readout | ocular rosacea | Positive | SEC Form 10-Q |
| Feb 2024Month disclosed | — | TARS | Topline readout | rosacea | Positive | SEC Form 10-Q |
| Feb 2024Month disclosed | — | TARS | Topline readout | rosacea | Positive | SEC Form 10-Q |
| Feb 2024Month disclosed | VK2735 | VKTX | Topline readout | obesity, in June 2025, we | Positive | SEC Form 10-Q |
February 2024: trial starts and primary completions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Feb 2024Month disclosed | olverembatinib (HQP1351) | AAPG | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| Feb 2024Month disclosed | alisertib (PB-8237) | PBYI | Trial start | with extensive-stage small cell lung cancer | Completed | SEC 8-K Exhibit 99.1 |
| Feb 2024Month disclosed | DNL126 | DNLI | Trial start | — | Completed | SEC Form 10-K |
| Feb 2024Month disclosed | ABS-101 | ABSI | Trial start | — | Completed | SEC Form 10-Q |
| Feb 2024Month disclosed | KB408 | KRYS | Trial start | with AATD | Completed | SEC Form 10-Q |
| Feb 2024Month disclosed | MNPR-101 | MNPR | Trial start | advanced cancers, and in April 2024, we launched the Phase 1 trial | Completed | SEC Form 10-Q |
| February 13, 2024 | CB-012 | CRBU | Trial start | — | Completed | SEC Form 10-K |
| Feb 2024Month disclosed | APHEXDA® (motixafortide) | BLRX | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| February 15, 2024 | FOLOTYN | CASIF | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| February 26, 2024 | KOMET-008 | KURA | Trial start | — | Completed | SEC Form 10-K |
2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps February 2024. They are on each drug page and in the calendar API.
Questions
What PDUFA dates are in February 2024?
2 PDUFA dates fell in February 2024: Amtagvi® (February 24), roluperidone (February 26). The FDA calendar also recorded 38 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.